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Abstract
Background:  Pertussis is a highly communicable, vaccine-preventable respiratory infection.
Immune response against this disease can be induced by infection or vaccination. Protection after
childhood vaccination is minimal after ten years. Our aim was to assess pertussis immunity state in
a population of healthy young medical students.
Methods: In this seroepidemiological survey, blood samples were obtained from 163 first-year
medical students in Hamedan University, Iran. Serum level of IgG against pertussis toxin (IgG-PT)
was measured by Enzyme-Linked Immunosorbent Assay (ELISA) method. For qualitative
assessment, IgG-PT levels more than 24 unit (U)/ml were considered positive. Data was analysed
qualitatively and quantitatively considering gender and age groups.
Results: There were 83 males and 80 females, with a mean age of 19.48 years, Prevalence of IgG-
PT was 47.6% with mean level of 71.7 u/ml (95% confidence interval: 68.1–75.3). No statistically
significant difference was observed with respect to sero-positivity of IgG-PT between males and
females (45 cases (54%) vs. 34 cases (42%); P = 0.06). Mean IgG-PT levels in males and females were
84 U/ml and 58.8 U/ml, respectively (P = 0.91).
Conclusion:  A considerable proportion of our study population with a positive history of
childhood vaccination for pertussis was not serologically immune to pertussis. A booster dose of
acellular pertussis vaccine may be indicated in Iranian, medical students regarding their serologic
conditions and outstanding role in health care systems.
Background
Pertussis is a very communicable disease caused by Borde-
tella pertussis and all age groups are susceptible to this res-
piratory infection [1]. The incidence of adult pertussis has
been estimated to be 200 to 500 per 100,000 person-
years, even in highly immunised populations [2-4], which
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is thought to reflect waning of the immunity from child-
hood vaccination. A total number of 314 suspicious cases
of pertussis, according to specimens collected by Dacron
swabs from nasopharynx, were reported in Iran in 2007.
Of this, 23 cases were diagnosed by pertussis using the
laboratory method of Real Time polymerase chain reac-
tion (PCR) [5]. Based on this report, the incidence of per-
tussis in Iran has decreased from 40% in 100,000
population in 1978 to 0.5% in 100,000 population in
2007.
Pertussis vaccines use in routine paediatric vaccination
programs has dramatically decreased the incidence and
complications of whooping cough in children [6], but
protection is thought to be minimal after 10 years without
boosting [7,8]. Because of concerns about the complica-
tions of whole-cell pertussis vaccines in older children
and adults, booster vaccinations have not been recom-
mended in these groups. In Iran, the pertussis vaccine is
administered in the 2nd, 4th, and 6th months of life, in
combination with two booster doses one administered in
month 18 and the other between the years 4 to 6.
In spite of the worldwide decline in the infection inci-
dence, the circulation of B. pertussis has not been elimi-
nated [9]. During recent decades, numerous studies have
documented that a significant percentage of prolonged
cough illnesses among adolescents and adults are due to
B. pertussis, with serological studies indicating a high rate
of unrecognized infections [10-13]. These groups act as a
source of infection for young infants who have not yet
completed their primary immunisation [7,14]. Acellular
pertussis vaccines have been evaluated in adolescents and
adults and confer a safe and effective protection against
pertussis in 92% of individuals [15]. However, universal
adult booster vaccination against pertussis has remained
controversial [7].
In this study, our aim was to determine the seroprevalence
of B. Pertussis among a group of adolescent first-year med-
ical students in the province of Hamedan, Iran in order to
provide local epidemiological data. This study, together
with other national studies, can supply evidence for rec-
ommending adult booster vaccination.
Methods
This cross-sectional seroepidemiological study was con-
ducted in healthy first-year medical students of Hamedan
University, Iran yet did not have exposure to hospital
environment. We considered the prevalence of pertussis
seropositivity, difference and confidence interval as 30%,
0.07, and 95%, respectively. According to our calcula-
tions, a sample size of 163 subjects was selected by simple
random method. Hence, all registration numbers of stu-
dents were listed, and by applying table of random num-
bers, the subjects were selected. All individuals were
asymptomatic while entering the study. Any respiratory
disease or conditions affecting immunocompetence were
of exclusion criteria. The subjects were classified into three
age groups: less than 19 years, 19–21 years and over 21
years.. The data related to age, gender and vaccination sta-
tus (according to their medical records) were obtained
during a primary interview. All participants had received
diphtheria, tetanus, whole pertussis vaccine (DTwP) man-
ufactured by Razi Vaccine & Serum Research Institute,
Tehran, Iran. Each dose of a o.5 ml of Razi-DTwP vaccine
contains 15 Lf diphtheria toxoid, 10 lF tetanus toxoid, 16
IU inactivated Bordetella Perussis bacterial cells, 0.3 to 0.6
mg aluminium phosphate (metal iron) and 0.01%
merthiolate according to thr instruction sheet provided by
the manufacturer [16].
For serological assessment, a venous blood sample of 3–5
ml was drawn. Immunoglobulin G (IgG) antibodies
against pertussis toxin, IgG-PT, were measured by
Enzyme-Linked Immunosorbent Assay (ELISA) kits and
results were interpreted according to the instructions pro-
vided by the manufacturer (IBL Immuno-Biological Labo-
ratories, Hamburg, Germany). For qualitative assessment,
IgG antibody levels more than 24 units (U)/ml were con-
sidered positive. Results were also analysed regarding
quantitative values.
Age and sex distribution at enrolment, the total preva-
lence of seropositive results and mean level of pertussis
IgG-PT in the studied subjects were calculated. In addi-
tion, the findings were stratified by the age groups. Differ-
ence in sero-positivity percentages was calculated using
the chi-square test. Quantitatively, t-test or one-way
ANOVA was used for examining mean IgG-PT levels
between the subgroups. Significance level was set at p <
0.05.
The study was approved by the Ethics Committee of our
university and informed consent was obtained from all
study participants.
Results and discussion
A total of 163 individuals (83 males and 80 females) were
recruited between March and June 2007. Mean age of the
cases was 19.48 years, ranging from 16 to 24 years. Of
these, 112 subjects were under 19 years, 40 were 19–21
years, and 11 were above 21 years old. History of pertussis
vaccination was positive in all subjects.
The total sero-prevalence rate of IgG-PT was 47.6%, with
a mean level of 71.7 U/ml (95% Confidence Interval:
68.1–75.3). Table 1 shows the frequency of IgG-PT posi-
tivity in the studied population. As presented, there were
no statistically significant differences neither regardingBMC Infectious Diseases 2009, 9:58 http://www.biomedcentral.com/1471-2334/9/58
Page 3 of 4
(page number not for citation purposes)
the frequency of sero-positivity between males and
females nor between the age groups.
Mean IgG-PT levels in males and females were 84 U/ml
and 58.8 U/ml, respectively (P = 0.91). In the analysis per-
formed regarding the age groups, mean IgG-PT level was
37 U/ml for <19 years, 82.7 U/ml for 19–21 years, and
49.2 U/ml for more than 21 year-old subjects. There were
no significant differences in the mean IgG-PT levels
among the age subgroups (p = 0.06).
According to obtained results, a considerable number of
medical students studied in an Iranian university from
both genders were not serologically immune to pertussis.
Since these students will have a major role in providing
health care services in both in-patient and out-patient
medical centres in the near future, it is of high priority to
perform complete vaccination programs through acellular
pertussis vaccines.
The importance of determination of IgG-PT in student
populations has been implicated in former studies. In a
study performed on students with chronic cough at the
University of California in 1992, 34 cases (26%) of infec-
tion with pertussis were found [12]. This led to this sug-
gestion that B. pertussis cough illnesses were endemic in
adolescents and adults and that they could be considered
as a source of outbreaks of the disease in susceptible chil-
dren. Subsequently, a number of studies among sympto-
matic and cough-free adolescents and adults have noted a
high percentage of the illnesses due to B. Pertussis infec-
tion [10,11].
We documented 47.6% seropositivity of IgG-PT in the
asymptomatic adolescent population between the ages of
19 and 24 years with a similar distribution between men
and women. According to national childhood vaccination
programme in Iran, all of our subjects had complete his-
tory of immunization against pertussis and none of them
received any adult booster vaccine dose. Our data is con-
sistent with another study in Iran (Isfahan) which
reported 48% positive serology for IgG-PT in adolescents
with prolonged cough [17]. The current statistics are also
in agreemenr with those from some other countries
[18,19].
In previous serological studies performed in different
countries, pertussis protective antibodies were reported in
a wide range of 30 to 97 percent. Vaccine antibodies begin
to wane 4 years after the last dose, thus immunity to per-
tussis vaccine diminishes to 0% to 20% over a 10-year
interval [7,8]. It has been shown that the seroprevalence
increases with age especially in countries with good child-
hood vaccination coverage [10-13]. The increment
between the adolescent and adult age group is assumed to
be due to natural pertussis infection. Repeated exposure to
the infection can also explain high level of pertussis anti-
body among unvaccinated adults.
Apart from being an adolescent population, our study
subjects were medical students. Health care workers have
more professional contacts with infectious patients than
general population. As our finding showed, half of the
studied population were seronegative. Therefore, This
group will be more susceptible to pertussis in the future
working as primary care providers in hospitals. Previous
outbreaks among healthcare workers and their patients
can signify the potentially harmful consequence of such
results [20-22]. However, it should be considered that
protection against B. pertussis is multifactorial. The pres-
ence of circulating antibodies does not guarantee the pro-
tection and the absence of antibodies does not imply that
an individual is necessarily susceptible.
Acellular pertussis vaccines confer safe and effective pro-
tection against pertussis in adolescents and adults [23]. In
March 2006, the American Academy of Paediatrics pub-
lished their recommendation that adolescents 11 to 18
years of age should receive a single dose of acellular per-
tussis vaccines combined with diphtheria and tetanus tox-
oids (DTaP) instead of tetanus and diphtheria toxoids
vaccine for booster immunisation.
In this study, only medical students were included. There-
fore, the obtained results may not be extended to adoles-
cents and adults living in the studied region. Also, we did
not follow these students in order to document the clini-
cal and serologic consequences of administration of a
booster dose of DTaP. Although all studied individuals
were students at the first year of medical school passing
their basic courses, we were not able to establish any doc-
umented contact with B. Pertussis.
Further studies are required to determine the incidence,
morbidity and complications of pertussis in adolescents
and adults to evaluate the cost-effectiveness of vaccina-
tion.
Table 1: The frequency of anti-PT seropositivity according to age 
and gender.
Parameters(total) N % p-value
Sex
Male (83) 45 54 0.06
Female (80) 34 42
Age group
<19 (112) 37 33 0.09
19–21 (40) 20 51
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Conclusion
A considerable proportion of the study population with a
positive history of childhood vaccination for pertussis was
not serologically immune to pertussis. A booster dose of
acellular pertussis vaccine may be indicated in Iranian,
medical students regarding their serologic conditions and
outstanding role in health care systems.
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